版本:
中国

BRIEF-CEL-SCI submits response to FDA in connection with partial clinical hold on phase 3 clinical trial

Nov 21 Cel-sci Corp :

* CEL-SCI Corp - submitted response to FDA regarding partial clinical hold of CEL-SCI's phase 3 clinical trial of its investigational drug multikine

* CEL-SCI submits response to fda in connection with partial clinical hold on phase 3 clinical trial Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐